Clinical Trials Logo

Clinical Trial Summary

The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.


Clinical Trial Description

To evaluate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria while on the SOC, as measured by a reduction in the 24-hour urinary protein excretion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04939116
Study type Interventional
Source Angion Biomedica Corp
Contact Brandy Dupee
Phone 857-378-4302
Email bdupee@angion.com
Status Recruiting
Phase Phase 2
Start date December 24, 2021
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Terminated NCT04051957 - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Phase 2
Completed NCT02226055 - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka N/A
Completed NCT02232763 - Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria Phase 3
Terminated NCT02057523 - Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Phase 4
Completed NCT00493727 - Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria N/A
Active, not recruiting NCT00565396 - Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Withdrawn NCT02882373 - Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury Phase 2
Completed NCT02327403 - Belatacept Conversion in Proteinuric Kidney Transplant Recipients Phase 2
Recruiting NCT01773382 - The Effects of Weight Reduction in IgA Nephropathy N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT01029002 - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease Phase 3
Withdrawn NCT00541619 - Sympathetic Overactivity in Essential Hypertension N/A
Withdrawn NCT00392132 - Impact of Screening Patients With HIV for Kidney Disease
Terminated NCT00001978 - Determination of Kidney Function
Recruiting NCT05457283 - A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Phase 3
Completed NCT04874753 - The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
Recruiting NCT02972346 - Availability Study of ACTH to Treat Children SRNS/SDNS N/A